NightHawk Biosciences, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From NightHawk Biosciences, Inc.
Monkeypox Vaccine, Drug Pipeline Grows Despite Signs Of Slowing Infections
Since its emergence in the spring, the monkeypox outbreak has spawned a small but growing pipeline of drugs and vaccines, many of them repurposed smallpox products.
Deal Watch: Ovid Teams With Gensaic On Phage-Derived, Gene-Delivered Therapies
Plus deals involving Glaukos/iVeena, Daré/Hennepin Life Sciences, Prevail/Lacerta, Chugai/Noile-Immune, Horizon/Q32, EpiAxis/Peptilogics and more.
Deal Watch: Roche, Pfizer, GSK Close Out 2021 With Licensing Transactions
Ahead of the usual flurry of deal-making in January, Roche gets retinal cell therapy candidate from Lineage Cell Therapeutics, Pfizer subsidiary Amplyx licenses antiviral candidate to Vera, and GSK expands neurology tie-up with Ligand.
Pipeline Watch Phase III Starts With IMO-2125, VX-659, And Tralokinumab
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
- Other Names / Subsidiaries
- Heat Biologics, Inc.
- Pelican Therapeutics, Inc.
- Seed-One Ventures
- University of Miami Miller School of Medicine
- Zolovax, Inc.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.